Lenze named head of Department of Psychiatry

Eric J. Lenze, MD, a leader in the treatment of psychiatric disorders in older adults and in devising innovative clinical trials to answer pressing public health problems, has been named the head of the Department of Psychiatry at Washington University School of Medicine in St. Louis. He will begin his new role Aug. 1. Lenze is the […]

Antidepressant may prevent severe COVID-19, follow-up study indicates

In the largest study yet to evaluate a common, low-cost antidepressant as a treatment for COVID-19, researchers from Washington University School of Medicine in St. Louis and from Canada and Brazil have found that the drug fluvoxamine prevents some of the most serious complications of COVID-19, sharply reducing the risk of hospitalization and death. The […]

Older people’s resilience during pandemic focus of $9 million grant

Researchers at Washington University School of Medicine in St. Louis have received a five-year, $9.1 million grant from the National Institute on Aging of the National Institutes of Health (NIH) to study resilience in older adults before and during the COVID-19 pandemic. The grant also will fund research into the pandemic’s cognitive and emotional effects […]

$6.2 million grant to fund Center for Perioperative Mental Health

The average person will undergo nine surgical procedures in his or her lifetime, and the periods before, during and after surgery are considered high risk regarding mental health, particularly among older adults. Depression and anxiety are especially common in older surgery patients; past research has demonstrated that about 40% of older surgical patients have mental […]

Finding a possible early treatment for COVID-19 in a 40-year-old antidepressant

The race to find vaccines for COVID-19 has dominated the headlines, but there’s been less news about how to keep people with COVID out of the hospital. Tonight, we’re going to tell you a story about one possible treatment. It’s called fluvoxamine. The generic drug was developed 40 years ago as an antidepressant and has […]

Doctors test popular anti-depressant to see if it fights off Covid-19

Doctors are running a clinical trial to see if a popular anti-depressant might keep someone from becoming severely ill with Covid-19. The researchers at Washington University of St. Louis are recruiting 1,100 people in the beginning stages of Covid-19 to test out the drug fluvoxamine, also known as Luvox. While an anti-depressant may seem like […]

Podcast: Vaccines have arrived but COVID-19 treatments progressing much more slowly

A new episode of our podcast, “Show Me the Science,” has been posted. At present, these podcast episodes are highlighting research and patient care on the Washington University Medical Campus as our scientists and clinicians confront the COVID-19 pandemic. COVID-19 vaccine development has been rapid and successful. Two vaccines that report more than 90% efficacy […]

Fluvoxamine may prevent serious illness in COVID-19 patients

In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Medicine in St. Louis have found that the drug fluvoxamine seems to prevent some of the most serious complications of the illness and make hospitalization and the need for supplemental oxygen […]

Podcast: Clinical trials launch to evaluate antimalarial, antidepressant drugs to treat COVID-19

Although anecdotal reports have suggested certain therapies help some patients, there still are no proven treatments for the disorder. In this episode, we discuss repurposing existing drugs to treat COVID-19. One study involves treating hospitalized patients. Another involves providing infected patients with a drug to take at home as a way to prevent them from […]

Study to evaluate antidepressant as potential COVID-19 treatment

Researchers at Washington University School of Medicine in St. Louis are launching a clinical trial in patients who have tested positive for COVID-19 but who are not sick enough to be hospitalized. The trial is investigating whether the antidepressant medication fluvoxamine, which is currently used to treat patients with obsessive-compulsive disorder (OCD), can be repurposed […]